CN112451734A - Application of monatomic catalyst as hemostatic agent - Google Patents
Application of monatomic catalyst as hemostatic agent Download PDFInfo
- Publication number
- CN112451734A CN112451734A CN202011340890.2A CN202011340890A CN112451734A CN 112451734 A CN112451734 A CN 112451734A CN 202011340890 A CN202011340890 A CN 202011340890A CN 112451734 A CN112451734 A CN 112451734A
- Authority
- CN
- China
- Prior art keywords
- carrier
- monatomic catalyst
- transition metal
- monatomic
- catalyst
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Catalysts (AREA)
Abstract
The invention belongs to the technical field of atomic catalysts, and relates to an application of a monoatomic catalyst in the medical field. The application of the monatomic catalyst as a hemostatic agent, wherein the monatomic catalyst consists of a carrier and transition metal, and the carrier is any one of zeolite molecular sieve, kaolin, calcium carbonate, calcium phosphate and talcum powder; the transition metal is one or more of iron, zinc and copper; the transition metal is anchored in the form of a single atom at a defect site on the surface of the support. The monatomic catalyst can be widely applied to the field of medicine, has an antibacterial and disinfection function, integrates the advantages of quick hemostasis, high wound healing speed, no scar and the like, and is a very excellent novel monatomic antibacterial and disinfection hemostatic agent.
Description
Technical Field
The invention belongs to the technical field of atomic catalysts, and relates to an application of a monoatomic catalyst in the medical field.
Background
The monatomic catalyst is a catalyst in which isolated single atoms are dispersed on a carrier, and is considered as a bridge for communicating a homogeneous catalyst and a heterogeneous catalyst because of its advantages of nearly 100% atom utilization, easy adjustment of active sites, easy separation from reactants, and the like. At present, the monatomic catalyst shows excellent activity, selectivity and stability in a series of reactions, such as water gas shift, hydrogenation, water electrolysis, oxygen reduction and the like, and the monatomic catalyst can be designed to effectively reduce the metal loading, improve the atom utilization rate and save the cost. In addition, the monoatomic structure in the monoatomic catalyst also provides a platform for the research of particle physics on an atomic model.
According to statistics, slight or severe wounds caused by exogenous factors mostly occur in traffic accidents, production accidents, war wounds, fighting blows, natural disasters and the like, and the accidents are high in incidence rate and disability rate and fatality rate. In mild cases, the wound tissue structure may be destroyed and the dysfunction may occur, in severe cases, the heart, lung, brain, liver, kidney and other organs may be damaged and endanger life. When slight or serious wound is caused, the most critical step is hemostasis, when a skin wound is torn or a mucous membrane is broken, the wound hemostasis treatment is incorrect or the wound is not treated in time, wound tissues are damaged, local tissues of the wound are damaged, the wound is extremely easy to be infected by bacteria, the bacteria are invaded, bred and kept in foreign bodies, acute inflammation, necrosis or suppuration of the wound can be caused, the life safety can be endangered in serious cases, and common pathogenic bacteria causing wound infection are as follows: staphylococcus aureus, staphylococcus epidermidis, pseudomonas aeruginosa, escherichia coli, enterococcus and the like. Wound infection not only reduces the body resistance and slows the wound healing speed, but also brings great inconvenience to daily life. Although the monatomic catalyst has been studied as a hot spot in the fields of energy, chemical industry, physics, and the like, and exhibits its catalytic action with high activity and high selectivity, no report has been found on the study of the monatomic catalyst in the medical field.
Disclosure of Invention
The present invention aims to provide the application of a monatomic catalyst as a hemostatic agent, and through the study on the hemostatic effect of the monatomic catalyst, the inventors have surprisingly found that the monatomic catalyst has a very excellent effect on antibacterial disinfection hemostasis, as will be clearly shown in the following tests.
The purpose of the invention is realized by the following technical scheme:
the monatomic catalyst is applied to the field of hemostasis as a hemostatic agent, and consists of a carrier and transition metal, wherein the carrier is any one of zeolite molecular sieve, kaolin, calcium carbonate, calcium phosphate and talcum powder; the transition metal is one or more of iron, zinc and copper; the transition metal is anchored in the form of a single atom at a defect site on the surface of the support.
Further, the mass ratio of the transition metal to the carrier is 1: 20-1: 200.
Further, the preparation method of the monatomic catalyst comprises the following steps:
1) stirring and mixing any one carrier of zeolite molecular sieve, kaolin, calcium carbonate, calcium phosphate and talcum powder with one or more metal salt solutions of iron, copper and zinc;
2) removing the solvent of the product obtained in the step 1), and grinding to obtain solid powder;
3) heating the solid powder obtained in the step 2), cooling and grinding to obtain the needed monatomic catalyst.
Furthermore, the particle size of the carrier is 2000-5000 meshes.
Further, in the step 1), the concentration of the metal salt solution is 5-200 g/L, the metal salt is any one of chloride, nitrate and sulfate, the solvent of the solution is deionized water, and the stirring time is 16-24 h.
Further, the heating treatment in the step 3) is heating for 1-12 hours at the temperature of 200-1000 ℃ in an atmosphere of 5-10 vt% hydrogen and argon mixed gas, and the grinding time is 20-40 min.
1. Compared with the traditional antibacterial, disinfectant and hemostatic material, the monatomic catalyst has more excellent antibacterial, disinfectant and hemostatic performances, does not need any auxiliary conditions, and can kill staphylococcus aureus, staphylococcus epidermidis, pseudomonas aeruginosa, escherichia coli, enterococcus and other common pathogenic bacteria causing wound infection in a broad spectrum.
2. The monatomic catalyst provided by the invention does not stimulate the wound and surrounding tissues, can better prevent bacteria from invading the wound, is beneficial to wound healing, and provides a good environment for wound healing.
3. The monatomic catalyst can be widely applied to the field of medicine, has an antibacterial and disinfection function, integrates the advantages of quick hemostasis, high wound healing speed, no scar and the like, and is a very excellent novel monatomic antibacterial and disinfection hemostatic agent.
Detailed Description
The present invention will be described in further detail with reference to specific examples, but the embodiments of the present invention are not limited to the scope of the examples. These examples are intended to illustrate the invention only and are not intended to limit the scope of the invention. In addition, various modifications may occur to those skilled in the art upon reading the present disclosure, and such equivalent variations are within the scope of the present invention as defined in the appended claims.
Example 1
Crushing and grinding a zeolite molecular sieve serving as a carrier uniformly, sieving the crushed zeolite molecular sieve by using a sieving machine, dissolving the processed zeolite molecular sieve with the granularity of 2000 meshes in 5g/L ferric chloride deionized water solution, wherein the mass ratio of the carrier to transition metal is 20:1, performing ultrasonic treatment on the obtained solution at the normal temperature of 100kHz for 30min to uniformly disperse the solution, stirring the solution by using a stirrer at the speed of 400r/min for 16 hours to uniformly disperse the solution, heating the obtained mixed solution to the boiling point of water, volatilizing the mixed solution at high temperature, evaporating the solvent to dryness, and fully grinding the mixed solution by using a ball mill at the rotating speed of 50r/min for 10min to obtain solid powder; heating the obtained solid powder to 200 ℃ in a tube furnace, carrying out heating treatment for 1h under the condition of 5 vt% (volume percentage concentration) of hydrogen-argon mixed gas atmosphere, cooling to room temperature, and grinding for 20min at the rotating speed of 50r/min by using a ball mill to obtain the needed monatomic catalyst, wherein transition metals contained in the prepared catalyst are anchored on defect sites on the surface of the carrier in a monatomic mode.
Example 2
Taking kaolin as a carrier, crushing, grinding uniformly, sieving by using a sieving machine, dissolving the kaolin in a 10g/L copper nitrate deionized water solution with the particle size of 3000 meshes after processing, wherein the mass ratio of the carrier to transition metal is 50:1, performing ultrasonic treatment on the obtained solution at 100kHz and normal temperature for 30min to disperse uniformly, then stirring by using a stirrer at 400r/min for 18 h to disperse uniformly, heating the obtained mixed solution to the boiling point of water, volatilizing at high temperature, evaporating the solvent, and fully grinding by using a ball mill at the rotating speed of 50r/min for 10min to obtain solid powder; and heating the obtained solid powder to 400 ℃ in a tubular furnace, carrying out heating treatment for 2h under the atmosphere of 6 vt% hydrogen-argon mixed gas, cooling to room temperature, and grinding for 25min at the rotating speed of 50r/min by using a ball mill to obtain the needed monatomic catalyst, wherein transition metals contained in the prepared catalyst are anchored on defect sites on the surface of the carrier in a monatomic mode.
Example 3
Grinding calcium carbonate serving as a carrier uniformly, sieving the ground calcium carbonate by using a sieving machine, dissolving the ground calcium carbonate into 50g/L zinc sulfate deionized water solution with the particle size of 4000 meshes, wherein the mass ratio of the carrier to transition metal is 100:1, ultrasonically dispersing the obtained solution uniformly for 30min at the normal temperature of 100kHz, stirring the solution for 20 h at the speed of 400r/min by using a stirrer, uniformly dispersing, heating the obtained mixed solution to the boiling point of water, volatilizing at high temperature, evaporating the solvent, fully grinding the mixed solution at the rotating speed of 50r/min by using a ball mill for 10min to obtain solid powder; and heating the obtained solid powder to 600 ℃ in a tubular furnace, carrying out heating treatment for 6h under the condition of atmosphere surrounding by 7 vt% hydrogen-argon mixed gas, cooling to room temperature, and grinding for 30min at the rotating speed of 50r/min by using a ball mill to obtain the required catalyst, wherein transition metals contained in the prepared catalyst are anchored on defect sites on the surface of the carrier in a monoatomic form.
Example 4
Grinding calcium phosphate serving as a carrier uniformly, sieving by using a sieving machine, dissolving the calcium phosphate serving as the carrier into 100g/L chloride deionized water solution (the chloride consists of ferric chloride and copper chloride in a mass ratio of 1: 1) with the processed particle size of 5000 meshes, performing ultrasonic treatment on the obtained solution at the normal temperature of 100kHz for 30min to uniformly disperse the solution, stirring the solution for 22 hours by using a stirrer at the speed of 400r/min, uniformly dispersing the solution, heating the obtained mixed solution to the boiling point of water, volatilizing the mixed solution at the high temperature, evaporating the solvent to dryness, and fully grinding the mixed solution at the rotating speed of 50r/min by using a ball mill for 10min to obtain solid powder; and heating the obtained solid powder to 800 ℃ in a tubular furnace, carrying out heating treatment for 8h under the condition of 8 vt% hydrogen-argon mixed gas atmosphere, cooling to room temperature, and grinding for 40min at the rotating speed of 50r/min by using a ball mill to obtain the required catalyst, wherein transition metals contained in the prepared catalyst are anchored on defect sites on the surface of the carrier in a monatomic mode.
Example 5
Grinding talcum powder serving as a carrier uniformly, sieving the ground talcum powder by using a sieving machine, dissolving the processed talcum powder with a particle size of 5000 meshes in 200g/L sulfate deionized water solution (sulfate is composed of ferric sulfate, copper sulfate and zinc sulfate in a mass ratio of 1:1: 2), wherein the mass ratio of the carrier to transition metal is 200:1, ultrasonically dispersing the obtained solution uniformly for 30min at the normal temperature of 100kHz, stirring the obtained solution for 24h by using a stirrer 400r/min, uniformly dispersing, heating the obtained mixed solution to the boiling point of water, volatilizing at high temperature, evaporating the solvent to dryness, and fully grinding the obtained mixed solution by using a ball mill at the rotating speed of 50r/min for 10min to obtain solid powder; and heating the obtained solid powder to 1000 ℃ in a tubular furnace, carrying out heating treatment for 12h under the atmosphere of 10 vt% hydrogen-argon mixed gas, cooling to room temperature, and grinding for 40min at the rotating speed of 50r/min by using a ball mill to obtain the required catalyst, wherein transition metals contained in the prepared catalyst are anchored on defect sites on the surface of the carrier in a monatomic mode.
The monatomic catalyst obtained in examples 1 to 5 was used as a hemostatic agent to perform a hemostatic test, a mouse was used as a study subject, the abdominal hair was removed, the test subject was sterilized, a wound 0.3cm deep was cut on the abdomen with a sterilized blade, blood was bled, an appropriate amount of monatomic catalyst was applied to the wound surface to stop bleeding, the bleeding time was observed and recorded, the average blood coagulation time was 10 seconds when the monatomic catalyst was used for the wound surface of a white mouse to stop bleeding, and the specific hemostatic effects were as shown in table 1:
TABLE 1 examples 1-5 hemostatic Effect
| Hemostasis time/s | |
| Example 1 | 12 |
| Example 2 | 13 |
| Example 3 | 8 |
| Example 4 | 9 |
| Example 5 | 8 |
| Mean time to hemostasis | 10 |
The test result shows that the monatomic catalyst can quickly stop bleeding, does not need any auxiliary condition, and can also inhibit pathogenic bacteria of wound infection in a broad spectrum manner to avoid wound infection.
Claims (6)
1. The application of the monatomic catalyst as a hemostatic agent, wherein the monatomic catalyst consists of a carrier and transition metal, and the carrier is any one of zeolite molecular sieve, kaolin, calcium carbonate, calcium phosphate and talcum powder; the transition metal is one or more of iron, zinc and copper; the transition metal is anchored in the form of a single atom at a defect site on the surface of the support.
2. The use according to claim 1, wherein the transition metal and the support are present in a mass ratio of 1:20 to 1: 200.
3. Use according to claim 1, characterized in that the preparation of the monatomic catalyst comprises the following steps:
1) stirring and mixing any one carrier of zeolite molecular sieve, kaolin, calcium carbonate, calcium phosphate and talcum powder with one or more metal salt solutions of iron, copper and zinc;
2) removing the solvent of the product obtained in the step 1), and grinding to obtain solid powder;
3) heating the solid powder obtained in the step 2), cooling and grinding to obtain the needed monatomic catalyst.
4. The use according to claim 3, wherein the carrier of step 1) has a particle size of 2000 to 5000 mesh.
5. The application of claim 4, wherein the concentration of the metal salt solution in the step 1) is 5-200 g/L, the metal salt is any one of chloride, nitrate and sulfate, the solvent of the solution is deionized water, and the stirring time is 16-24 h.
6. The use according to claim 3, wherein the heating treatment in step 3) is heating at a temperature of 200-1000 ℃ for 1-12 h in an atmosphere of 5-10 vt% hydrogen-argon mixture, and the grinding time is 20-40 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011340890.2A CN112451734A (en) | 2020-11-25 | 2020-11-25 | Application of monatomic catalyst as hemostatic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011340890.2A CN112451734A (en) | 2020-11-25 | 2020-11-25 | Application of monatomic catalyst as hemostatic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112451734A true CN112451734A (en) | 2021-03-09 |
Family
ID=74808143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011340890.2A Pending CN112451734A (en) | 2020-11-25 | 2020-11-25 | Application of monatomic catalyst as hemostatic agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112451734A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112869264A (en) * | 2021-04-01 | 2021-06-01 | 联科华技术有限公司 | Medical protective facial mask of monatomic with antibiotic antiviral function |
| CN113616847A (en) * | 2021-09-03 | 2021-11-09 | 山西中医药大学 | Calamine hemostatic compound based on Y molecular sieve carrier and preparation thereof |
| CN113827488A (en) * | 2021-11-15 | 2021-12-24 | 黄维滢 | Antibacterial body-perfuming body-refreshing emulsion and preparation method thereof |
| CN113896950A (en) * | 2021-09-28 | 2022-01-07 | 联科华技术有限公司 | Monoatomic zinc material capable of replacing zinc oxide used in rubber field and preparation method thereof |
| CN114053158A (en) * | 2021-11-15 | 2022-02-18 | 黄维滢 | Monoatomic material with antibacterial and anti-inflammatory effects and capable of promoting skin repair and preparation method and application thereof |
| EP4066649A1 (en) * | 2021-04-01 | 2022-10-05 | Linkway Technology Co., Ltd. | Single atomic zinc additive for use in feeds and preparation method thereof |
Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02203857A (en) * | 1989-02-02 | 1990-08-13 | Noboru Horayama | Styptic band |
| CN1227107A (en) * | 1998-02-23 | 1999-09-01 | 静缘 | External use hemostatic powder |
| US20080199539A1 (en) * | 2007-02-21 | 2008-08-21 | Sarah Baker | Hemostatic compositions and methods of use |
| RU2333002C1 (en) * | 2007-04-17 | 2008-09-10 | Меграбян Казарос Аршалуйсович | Haemostatic preparation |
| CN101416982A (en) * | 2008-11-27 | 2009-04-29 | 浙江大学 | Preparation method of external natural carbonate emergency life-saving hemostat |
| CN102000111A (en) * | 2010-12-23 | 2011-04-06 | 范杰 | Preparation method of emergency survival hemostatic based on natural zeolite in Jinyun of Zhejiang |
| CN102274541A (en) * | 2011-09-09 | 2011-12-14 | 天津禹王生物医药科技有限公司 | Hemostatic material |
| CN103271942A (en) * | 2013-05-27 | 2013-09-04 | 浙江大学 | Method for preparing nano silver-kaolinite compound by using hydrated kaolinite as carrier |
| EP3062830A1 (en) * | 2013-10-31 | 2016-09-07 | BK Giulini GmbH | Haemostatic composition comprising crystalline polyphosphate |
| WO2017143419A1 (en) * | 2016-02-22 | 2017-08-31 | Universidade Estadual Paulista Julio De Mesquita Filho | Method for producing nanozeolites with hemostatic activity, and thus obtained product |
| CN107213508A (en) * | 2017-06-09 | 2017-09-29 | 中南大学 | A kind of oxides-containing iron/nano kaoline compound hemostatic agent and preparation method thereof |
| CN109481731A (en) * | 2019-01-23 | 2019-03-19 | 中南大学 | A kind of nano-oxide/kaolin compound hemostatic anti-biotic material, functions of stanching and promoting healing dressing and preparation method thereof |
| CN109966543A (en) * | 2019-03-22 | 2019-07-05 | 瞿应良 | A kind of preparation method of wound hemostasis packet and porous hemostat particle |
| CN111266099A (en) * | 2020-02-24 | 2020-06-12 | 联科华技术股份有限公司 | Series of inorganic antibacterial mildew-proof monatomic catalysts and preparation method thereof |
| CN111956863A (en) * | 2020-07-20 | 2020-11-20 | 广东省微生物研究所（广东省微生物分析检测中心） | Anion-cation co-doped nano calcium phosphate antibacterial material and preparation method thereof |
-
2020
- 2020-11-25 CN CN202011340890.2A patent/CN112451734A/en active Pending
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02203857A (en) * | 1989-02-02 | 1990-08-13 | Noboru Horayama | Styptic band |
| CN1227107A (en) * | 1998-02-23 | 1999-09-01 | 静缘 | External use hemostatic powder |
| US20080199539A1 (en) * | 2007-02-21 | 2008-08-21 | Sarah Baker | Hemostatic compositions and methods of use |
| RU2333002C1 (en) * | 2007-04-17 | 2008-09-10 | Меграбян Казарос Аршалуйсович | Haemostatic preparation |
| CN101416982A (en) * | 2008-11-27 | 2009-04-29 | 浙江大学 | Preparation method of external natural carbonate emergency life-saving hemostat |
| CN102000111A (en) * | 2010-12-23 | 2011-04-06 | 范杰 | Preparation method of emergency survival hemostatic based on natural zeolite in Jinyun of Zhejiang |
| CN102274541A (en) * | 2011-09-09 | 2011-12-14 | 天津禹王生物医药科技有限公司 | Hemostatic material |
| CN103271942A (en) * | 2013-05-27 | 2013-09-04 | 浙江大学 | Method for preparing nano silver-kaolinite compound by using hydrated kaolinite as carrier |
| EP3062830A1 (en) * | 2013-10-31 | 2016-09-07 | BK Giulini GmbH | Haemostatic composition comprising crystalline polyphosphate |
| WO2017143419A1 (en) * | 2016-02-22 | 2017-08-31 | Universidade Estadual Paulista Julio De Mesquita Filho | Method for producing nanozeolites with hemostatic activity, and thus obtained product |
| CN107213508A (en) * | 2017-06-09 | 2017-09-29 | 中南大学 | A kind of oxides-containing iron/nano kaoline compound hemostatic agent and preparation method thereof |
| CN109481731A (en) * | 2019-01-23 | 2019-03-19 | 中南大学 | A kind of nano-oxide/kaolin compound hemostatic anti-biotic material, functions of stanching and promoting healing dressing and preparation method thereof |
| CN109966543A (en) * | 2019-03-22 | 2019-07-05 | 瞿应良 | A kind of preparation method of wound hemostasis packet and porous hemostat particle |
| CN111266099A (en) * | 2020-02-24 | 2020-06-12 | 联科华技术股份有限公司 | Series of inorganic antibacterial mildew-proof monatomic catalysts and preparation method thereof |
| CN111956863A (en) * | 2020-07-20 | 2020-11-20 | 广东省微生物研究所（广东省微生物分析检测中心） | Anion-cation co-doped nano calcium phosphate antibacterial material and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 易磊: "《妙用草本良方》", 31 January 2017, 北京：中医古籍出版社 * |
| 滕玥: "无机止血剂的现状与发展", 《临床急诊杂质》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112869264A (en) * | 2021-04-01 | 2021-06-01 | 联科华技术有限公司 | Medical protective facial mask of monatomic with antibiotic antiviral function |
| EP4066649A1 (en) * | 2021-04-01 | 2022-10-05 | Linkway Technology Co., Ltd. | Single atomic zinc additive for use in feeds and preparation method thereof |
| CN113616847A (en) * | 2021-09-03 | 2021-11-09 | 山西中医药大学 | Calamine hemostatic compound based on Y molecular sieve carrier and preparation thereof |
| CN113896950A (en) * | 2021-09-28 | 2022-01-07 | 联科华技术有限公司 | Monoatomic zinc material capable of replacing zinc oxide used in rubber field and preparation method thereof |
| CN113896950B (en) * | 2021-09-28 | 2022-05-13 | 联科华技术有限公司 | Monoatomic zinc material capable of replacing zinc oxide used in rubber field and preparation method thereof |
| CN113827488A (en) * | 2021-11-15 | 2021-12-24 | 黄维滢 | Antibacterial body-perfuming body-refreshing emulsion and preparation method thereof |
| CN114053158A (en) * | 2021-11-15 | 2022-02-18 | 黄维滢 | Monoatomic material with antibacterial and anti-inflammatory effects and capable of promoting skin repair and preparation method and application thereof |
| CN113827488B (en) * | 2021-11-15 | 2023-06-30 | 黄维滢 | Antibacterial body-fragrant body-refreshing emulsion and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112451734A (en) | Application of monatomic catalyst as hemostatic agent | |
| US4828832A (en) | Method of manufacturing a composition for treating skin lesions | |
| CN112336912B (en) | Monoatomic antibacterial disinfecting hemostatic hydrogel and preparation method thereof | |
| TWI702051B (en) | Efficient nano spot lightening, brightening, moisturizing activator and its preparation method | |
| Chundran et al. | Effect of neem leaves extract (Azadirachta indica) on wound healing | |
| CN107258774A (en) | A kind of antibacterial material with slow-releasing and controlled-releasing action and preparation method and application | |
| CN109646712A (en) | A kind of sulikol liquid dressing and preparation method thereof | |
| Yang et al. | Multifunctional nanoreactors with nutrient consumption and ROS generation capabilities for antibacterial and skin repair | |
| CN105561370B (en) | A kind of hemostatic material and preparation method thereof | |
| CN101130105A (en) | Povidone-iodine hydrogel wound dressing and radiation preparation method thereof | |
| CN119318731B (en) | A sprayable hydrogel for healing bacterial infection wounds and preparation method thereof | |
| CN102697804B (en) | Solid molecular iodine disinfectant and preparation method thereof | |
| CN104983722A (en) | Spraying film forming agent composition used for removing skin scars and preparation method of composition | |
| Liang et al. | Janus nanozyme–drug nanosystems for synergistic anti-inflammatory treatment of nasal polyps | |
| CN108578540A (en) | A kind of biologic formulation and preparation method thereof for inhibiting scar and promoting wound healing | |
| RU2383349C1 (en) | Wound-healing medication and method of obtaining it | |
| CN112402684A (en) | Monoatomic antibacterial disinfecting hemostatic gauze and preparation method thereof | |
| RU2426525C1 (en) | Preventive ointment for diabetic foot | |
| CN114848891B (en) | Compound wound repair dressing containing mussel-like mucin and preparation method thereof | |
| CN106421878A (en) | Rapidly hemostatic and antibacterial carboxylic starch-polylysine microsphere and preparation method thereof | |
| Liu et al. | Propelling CuCo-based nanozyme design to new heights through triple enzyme-like power for high-efficiency bacterial eradication | |
| EP0393190A1 (en) | Copolymers of vinyl alcohol with vinyl acetate, cross-linked by glutaric dialdehyde, method of obtaining them and a phramaceutical preparation based thereon | |
| CN118557773B (en) | Bismuth-containing functional auxiliary agent, antibacterial healing-promoting bismuth-containing dressing and preparation method thereof | |
| Dangi et al. | Wound healing efficacy of green synthesized silver nanoparticles from tectona grandis wood flour extract in Wistar rats | |
| KR102591389B1 (en) | A silver and platinum nano-colloidal solution containing ortho-hydrogenated hydrogen water and a method for producing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |